China Pharma Holdings, Inc. (NYSEAMERICAN:CPHI) Short Interest Update

China Pharma Holdings, Inc. (NYSEAMERICAN:CPHIGet Rating) saw a large drop in short interest in the month of April. As of April 30th, there was short interest totalling 145,600 shares, a drop of 18.5% from the April 15th total of 178,700 shares. Based on an average daily volume of 169,800 shares, the days-to-cover ratio is currently 0.9 days. Currently, 0.6% of the company’s shares are sold short.

NYSEAMERICAN CPHI remained flat at $$0.24 during midday trading on Wednesday. The company’s stock had a trading volume of 40,651 shares, compared to its average volume of 179,046. The company has a market cap of $11.59 million, a PE ratio of -2.67 and a beta of 0.25. China Pharma has a 1-year low of $0.20 and a 1-year high of $1.12.

An institutional investor recently raised its position in China Pharma stock. Renaissance Technologies LLC lifted its holdings in China Pharma Holdings, Inc. (NYSEAMERICAN:CPHIGet Rating) by 43.7% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 700,649 shares of the company’s stock after purchasing an additional 213,170 shares during the quarter. Renaissance Technologies LLC owned about 1.61% of China Pharma worth $391,000 as of its most recent SEC filing. 2.64% of the stock is currently owned by institutional investors.

China Pharma Company Profile (Get Rating)

China Pharma Holdings, Inc develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products primarily to hospitals and private retailers in the People's Republic of China. The company offers products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions.

Read More

Receive News & Ratings for China Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Pharma and related companies with's FREE daily email newsletter.